Get the Stockscreener App
72.60
0.19%
-0.14
After Hours:
72.60
Avidity Biosciences Inc stock is traded at $72.60, with a volume of 1.12M.
It is down -0.19% in the last 24 hours and up +0.64% over the past month.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$72.74
Open:
$72.61
24h Volume:
1.12M
Relative Volume:
0.25
Market Cap:
$10.94B
Revenue:
$10.73M
Net Income/Loss:
$-455.74M
P/E Ratio:
-20.41
EPS:
-3.5569
Net Cash Flow:
$-502.70M
1W Performance:
+0.12%
1M Performance:
+0.64%
6M Performance:
+114.03%
1Y Performance:
+140.96%
1-Day Range:
$72.55
$72.72
1-Week Range:
$72.45
$72.74
52-Week Range:
$21.51
$72.74
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
72.60 | 10.96B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
814.74 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.98 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.32 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Roth Capital | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Bernstein | Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Jun-11-25 | Initiated | Raymond James | Strong Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Avidity Biosciences CEO Boyce sells $1.04 million in stock By Investing.com - Investing.com Canada
Avidity Biosciences (NASDAQ:RNA) CFO Sells $329,067.90 in Stock - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Insider Sells $354,642.75 in Stock - MarketBeat
Avidity Biosciences (NASDAQ:RNA) CEO Sells $1,042,338.15 in Stock - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Insider Teresa Mccarthy Sells 2,929 Shares - MarketBeat
Avidity Biosciences CMO sells $354k in stock - Investing.com
Avidity Biosciences CFO MacLean sells $329k in stock - Investing.com
Avidity Biosciences stock hits all-time high at $72.70 By Investing.com - Investing.com Nigeria
Avidity Biosciences (NASDAQ:RNA) Reaches New 12-Month HighHere's What Happened - MarketBeat
Avidity Biosciences stock hits all-time high at $72.70 - Investing.com
Weekly Earnings: Can Kosmos Energy Ltd expand into new marketsQuarterly Performance Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Retail Trends: Is Avidity Biosciences Inc a cyclical or defensive stockJuly 2025 Rallies & Low Volatility Stock Recommendations - baoquankhu1.vn
Avidity reports FTC granted request for early termination of HSR waiting period - MSN
Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring the Biotech Firm’s 434% Revenue Growth and Future Prospects - DirectorsTalk Interviews
Can Avidity Biosciences Inc continue delivering strong returnsTrade Ideas & Pattern Based Trade Signal System - baoquankhu1.vn
Aug PostEarnings: Can Avidity Biosciences Inc outperform in the next rallyJuly 2025 Volume & AI Driven Stock Price Forecasts - baoquankhu1.vn
Avidity Biosciences (NASDAQ:RNA) Hits New 1-Year HighHere's What Happened - MarketBeat
Avidity Biosciences stock hits all-time high at 72.63 USD By Investing.com - Investing.com India
Avidity Biosciences stock hits all-time high at 72.63 USD - Investing.com
Novartis (NYSE: NVS) details Avidity deal and Atrium SpinCo plans - Stock Titan
Understanding the Setup: (RNA) and Scalable Risk - Stock Traders Daily
Hedge Fund Moves: Can Avidity Biosciences Inc. stock sustain free cash flow growthMarket Trend Review & Real-Time Buy Signal Alerts - moha.gov.vn
Earnings Beat: Will Avidity Biosciences Inc outperform tech stocksJuly 2025 Levels & Fast Moving Trade Plans - baoquankhu1.vn
Avidity Biosciences, Inc. (RNA) Stock Analysis: Impressive Revenue Growth Amidst Biotech Sector Challenges - DirectorsTalk Interviews
Avidity Biosciences, Inc. Appoints Stephen Moran as Managing Director - marketscreener.com
Insider Selling: Avidity Biosciences (NASDAQ:RNA) CEO Sells 8,576 Shares of Stock - MarketBeat
Insider Selling: Avidity Biosciences (NASDAQ:RNA) Insider Sells 2,374 Shares of Stock - MarketBeat
Charles Calderaro III Sells 3,727 Shares of Avidity Biosciences (NASDAQ:RNA) Stock - MarketBeat
Novartis to acquire Avidity Biosciences for about $12B - MSN
W. Michael Flanagan Sells 2,373 Shares of Avidity Biosciences (NASDAQ:RNA) Stock - MarketBeat
Why Avidity Biosciences Inc. stock attracts high net worth investors2025 Historical Comparison & Free Fast Entry Momentum Trade Alerts - ulpravda.ru
Will Avidity Biosciences Inc. stock gain from strong economyOil Prices & Free Verified High Yield Trade Plans - ulpravda.ru
Avidity Biosciences (NASDAQ:RNA) Stock Crosses Above Fifty Day Moving AverageHere's Why - MarketBeat
Avidity Biosciences, Inc. (RNA) Stock Analysis: Navigating a 434% Revenue Surge and Strategic Clinical Trials - DirectorsTalk Interviews
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James - MSN
The Technical Signals Behind (RNA) That Institutions Follow - Stock Traders Daily
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Is Avidity Biosciences Inc a good long term investmentStock Price Divergence & Market Monitoring and Alerts - earlytimes.in
Avidity Biosciences Earnings Notes - Trefis
Is Avidity Biosciences Inc. stock resilient to inflationSupport Zone Identification & High Return Trading Ideas - bollywoodhelpline.com
Avidity Biosciences, Inc. (RNA) Stock Analysis: Navigating a 434% Revenue Surge and Potential 3.47% Upside - DirectorsTalk Interviews
CEO Moves: Is Avidity Biosciences Inc stock a buy on dipsSwing Trade & Weekly High Return Opportunities - moha.gov.vn
Novartis to acquire Avidity Biosciences for about $12 billion - MSN
Assenagon Asset Management S.A. Has $2 Million Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
How Avidity Biosciences Inc. stock valuations compare to rivalsQuarterly Market Summary & Risk Adjusted Buy/Sell Alerts - Улправда
Exit Recap: Is Avidity Biosciences Inc. stock resilient to inflationJuly 2025 Spike Watch & Long-Term Growth Plans - ulpravda.ru
Avidity Biosciences stock hits all-time high at 72.23 USD By Investing.com - Investing.com South Africa
Avidity Biosciences stock hits all-time high at 72.23 USD - Investing.com
Officer Calderaro III Surrenders 9,726 Of Avidity Biosciences Inc [RNA] - TradingView — Track All Markets
Officer Flanagan Surrenders 13,695 Of Avidity Biosciences Inc [RNA] - TradingView — Track All Markets
Officer Mosbrooker Surrenders 47,990 Of Avidity Biosciences Inc [RNA] - TradingView — Track All Markets
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.92%
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):